Citations

Clear

5 citation(s) found for "Mcrae, Alison".

Unraveling the Variability of Human Satiation: Implications for Precision Obesity Management
Cifuentes, Lizeth , Añazco, Diego , Fansa, Sima , McRae, Alison , Madhusudhan, Sunil, Kolkin, Elle, Ryks, Michael, Harmsen, William S. , Dayyeh, Barham Abu, Hensrud, Donald D. , Camilleri, Michael , Acosta, Andrés , Acosta, Andres , Anazco, Diego , McRae, Alison , Abu Dayyeh, Barham, Hensrud, Donald, Camilleri, M , O'Connor, Timothy R , Hurtado, Maria D. , Ghusn, Wissam , Campos, Alejandro , Ciotlos, Serban, Dayyeh, Barham K. Abu

Mayo Clinic

No container title available | May 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4402499/v1 | PMID 38826309 Get It

Abstract Satiation is the physiologic process that regulates meal size and termination, and it is quantified by the calories consumed to reach satiation. Given its role in energy intake, changes in satiation contribute to obesity's pathogenesis. Our study employed a protocolized approach to study the components of food intake regulation including a standardized breakfast, a gastric emptying study, appetite sensation testing, and a satiation measurement by an ad libitummeal test. These studies revealed that satiation is highly variable among individuals, and while baseline characteristics, anthropometrics, body composition and hormones, contribute to this variability, these factors do not fully account for it. To address this gap, we explored the role of a germline polygenic risk score, which demonstrated a robust association with satiation. Furthermore, we developed a machine-learning-assisted gene risk score to predict satiation and leveraged this prediction to anticipate responses to anti-obesity medications. Our findings underscore the significance of satiation, its inherent variability, and the potential of a genetic risk score to forecast it, ultimately allowing us to predict responses to different anti-obesity interventions.
S1667 Appetite-Related Physiological Adaptations to a Low-Calorie, Low-Fat Diet in Obesity Compared to Normal Weight
Mcrae, Alison, Ricardo, Maria Laura, Cifuentes, Lizeth , Calderon, Gerardo, Gonzalez, Daniel, Hurtado, Maria D. , Acosta, Andrés

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S1247-S1247

10.14309/01.ajg.0000956308.01115.ce Get It

Effect of caloric intake and macronutrient composition on intestinal cholesterol absorption and bile acids in patients with obesity
Hashem, Anas , Cifuentes, Lizeth , Ricardo-Silgado, Maria Laura , Gonzalez‐Izundegui, Daniel, Campos, Alejandro , Mcrae, Alison, Franks, Shawna, Burton, Duane, Petterson, Xuan-Mai, Camilleri, Michael , Hashem, Anas Mohamad , Calderon, Gerardo, Gonzalez-Izundegui, Daniel, Hurtado, Maria Daniela , Lanza, Ian R , Camilleri, M , Acosta, Andres , Campos, Alejandro , Calderon-Lopez, Gerardo , Hurtado, Maria D. , Lanza, Ian R. , Acosta, Andrés

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | June 21, 2022 | Volume: 323 | Issue: 3 | Pages: G157-G164

10.1152/ajpgi.00108.2022 | PMID 35727128 Get It

We show how switching from a regular diet to an HCHF increases cholesterol absorption in patients with normal weight and obesity. The decrease in cholesterol absorption from an HCHF to an LCLF, on the other hand, was only seen in normal-weight controls, underlining the importance of body weight in this regulation. In addition, changes in caloric and fat content had an immediate and direct effect on hepatic bile acid production.
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
Acosta, Andrés , Camilleri, Michael , Dayyeh, Barham Abu, Mcrae, Alison, Rossini, William, Burton, Duane D. , Clark, Matthew M. , Abu Dayyeh, Barham, Calderon, Gerardo, Burton, Duane, Acosta, Andres , Calderon-Lopez, Gerardo , González, Daniel , Singh, Sneha

Mayo Clinic

Obesity | March 24, 2021 | Volume: 29 | Issue: 4 | Pages: 662-671

10.1002/oby.23120 | PMID 33759389 Get It

ObjectiveLittle is known about the predictors of response to obesity interventions.MethodsIn 450 participants with obesity, body composition, resting energy expenditure, satiety, satiation, eating behavior, affect, and physical activity were measured by validated studies and questionnaires. These variables were used to classify obesity phenotypes. Subsequently, in a 12‐month, pragmatic, real‐world trial performed in a weight management center, 312 patients were randomly assigned to phenotype‐guided treatment or non‐phenotype‐guided treatment with antiobesity medications: phentermine, phentermine/topiramate, bupropion/naltrexone, lorcaserin, and liraglutide. The primary outcome was weight loss at 12 months.ResultsFour phenotypes of obesity were identified in 383 of 450 participants (85%): hungry brain (abnormal satiation), emotional hunger (hedonic eating), hungry gut (abnormal satiety), and slow burn (decreased metabolic rate). In 15% of participants, no phenotype was identified. Two or more phenotypes were identified in 27% of patients. In the pragmatic clinical trial, the phenotype‐guided approach was associated with 1.75‐fold greater weight loss after 12 months with mean weight loss of 15.9% compared with 9.0% in the non‐phenotype‐guided group (difference −6.9% [95% CI −9.4% to −4.5%], P < 0.001), and the proportion of patients who lost >10% at 12 months was 79% in the phenotype‐guided group compared with 34% with non‐phenotype‐guided treatment group.ConclusionsBiological and behavioral phenotypes elucidate human obesity heterogeneity and can be targeted pharmacologically to enhance weight loss.
Contamination of Single Fluid-Filled Intragastric Balloons with Orogastric Fluid is not Associated with Hyperinflation: An Ex-vivo Study and Systematic Review of Literature
Hawa, Fadi , McRae, Alison , Vargas, Eric J. , Acosta, Andrés , Bazerbachi, Fateh , Dayyeh, Barham K. Abu

Mayo Clinic

No container title available | March 18, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-318739/v1 Get It

Abstract Background Spontaneous hyperinflation is reported to the Food and Drug Administration as a complication of intragastric balloons. It is postulated that orogastric contamination of the intragastric balloon may cause this phenomenon. We sought to investigate the effects of intentional balloon contamination with gastric contents on intragastric balloon diameter and contents, whether methylene blue plays a role in preventing spontaneous hyperinflation, and review the available literature on spontaneous hyperinflation. Methods Four pairs of balloons with different combinations of sterile saline, contaminants, and methylene blue were incubated in a 37° Celsius water bath for 6 months to simulate physiological conditions with serial measurements of balloon diameter. Our findings were compared against a systematic review across multiple databases to summarize the available literature. Results Balloon mean diameter decreased from 33.5 cm ± 0.53 cm to 28.5 cm ± 0.46 cm (p < 0.0001). No significant differences were seen with the methylene blue group. Only 11 cases were found reported in the literature. Conclusions Despite contaminating intragastric balloons with gastric aspirates, hyperinflation did not occur, and other factors may be in play to account for this phenomenon, when observed. Rates of hyperinflation remain under-reported in the literature. Further controlled experiments are needed.